



11-1-02
B0 - Seq
A

Please type a plus sign (+) inside this box →

Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL <small>(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))</small>		Attorney Docket No. 6632.US.O2
		First Inventor or Application Identifier F. Haviv, et. al.
		Title N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY
		Express Mail Label No. EL384167615US

APPLICATION ELEMENTS <small>See MPEP chapter 600 concerning utility patent application contents.</small>		ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
<p>1. <input checked="" type="checkbox"/> * Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)</p> <p>2. <input checked="" type="checkbox"/> Specification [Total Pages 93] (preferred arrangement set forth below)</p> <ul style="list-style-type: none"> - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure <p>3. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets 1]</p> <p>4. Oath or Declaration [Total Pages 1]</p> <ul style="list-style-type: none"> a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 C.F.R. § 1.63(d)) (for continuation/divisional with Box 16 completed) <ul style="list-style-type: none"> i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b). 		
<p>5. <input type="checkbox"/> Microfiche Computer Program (Appendix)</p> <p>6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)</p> <ul style="list-style-type: none"> a. <input checked="" type="checkbox"/> Computer Readable Copy b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy) c. <input checked="" type="checkbox"/> Statement verifying identity of above copies 		
ACCOMPANYING APPLICATION PARTS		
<p>7. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))</p> <p>8. <input type="checkbox"/> 37 C.F.R. §3.73(b) Statement <input type="checkbox"/> Power of (when there is an assignee) <input type="checkbox"/> Attorney</p> <p>9. <input type="checkbox"/> English Translation Document (if applicable)</p> <p>10. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>11. <input type="checkbox"/> Preliminary Amendment</p> <p>12. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)</p> <p>* Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application (PTO/SB-09-12) <input type="checkbox"/> Status still proper and desired</p> <p>13. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)</p> <p>14. <input type="checkbox"/> Other: Application Cover Sheet</p>		

***NOTE FOR ITEMS 1 & 13 IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).**

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

Continuation Divisional Continuation-in-part (CIP) of prior application No: **60/166,924**

Prior application information: Examiner _____ Group / Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

<input type="checkbox"/> Customer Number or Bar Code Label / (Insert Customer No. or Attach bar code label here)	or <input type="checkbox"/> Correspondence address below	
<p>Name Steven F. Weinstock</p> <p>Abbott Laboratories</p>		
<p>Address Department 377 / AP6D-2</p> <p>100 Abbott Park Road</p>		
City Abbott Park	State IL	Zip Code 60064-6050
Country USA	Telephone (947) 937-0042	Fax (847) 938-2623

Name (Print/Type) Gregory W. Steele	Registration No. (Attorney/Agent) 33,796
Signature	Date 10/31/00

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL

Patent fees are subject to annual revision on October 1.

These are the fees effective October 1, 1997.

Small Entity payments must be supported by a small entity statement, otherwise large entity fees must be paid. See Forms PTO/SB/09-12. See 37 C.F.R. §§1.27 and 1.28.

TOTAL AMOUNT OF PAYMENT (\$ 1,052.00)

Complete if Known

Application Number	(not yet assigned)
Filing Date	October 31, 2000
First Named Inventor	F. Haviv, et. al.
Examiner Name	(not yet assigned)
Group / Art Unit	(not yet assigned)
Attorney Docket No.	6632.US.O2

METHOD OF PAYMENT (check one)

1. The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number
Deposit Account Name

01-0025

Abbott Laboratories

- Charge Any Additional Fee Required Under 37 C.F.R. §§1.16 and 1.17
- Charge the Issue Fee Set in 37 C.F.R. §1.18 at the Mailing of the Notice of Allowance

- 2.
-
- Payment Enclosed:

 Check Money Order Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid	
101	790	201	395 Utility filing fee	710.00
106	330	206	165 Design filing fee	
107	540	207	270 Plant filing fee	
108	790	208	395 Reissue filing fee	
114	150	214	75 Provisional filing fee	
SUBTOTAL (1) (\$)			710.00	

2. EXTRA CLAIM FEES

Total Claims	-20** =	Extra Claims	Fee from below	Fee Paid
39	-20** =	19	18.00	342.00
Independent Claims	3	-3** =	0	80.00 = 0.00
Multiple Dependent				

**or number previously paid, if greater; For Reissues, see below

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
103	22	203 11 Claims in excess of 20
102	82	202 41 Independent claims in excess of 3
104	270	204 135 Multiple dependent claim, if not paid
109	82	209 41 ** Reissue independent claims over original patent
110	22	210 11 ** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2) (\$)		

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
105	130	205 65 Surcharge - late filing fee or oath	
127	50	227 25 Surcharge - late provisional filing fee or cover sheet	
139	130	139 130 Non-English specification	
147	2,520	147 2,520 For filing a request for reexamination	
112	920*	112 920* Requesting publication of SIR prior to Examiner action	
113	1,840*	113 1,840* Requesting publication of SIR after Examiner action	
115	110	215 55 Extension for reply within first month	
116	400	216 200 Extension for reply within second month	
117	950	217 475 Extension for reply within third month	
118	1,510	218 755 Extension for reply within fourth month	
128	2,060	228 1,030 Extension for reply within fifth month	
119	310	219 155 Notice of Appeal	
120	310	220 155 Filing a brief in support of an appeal	
121	270	221 135 Request for oral hearing	
138	1,510	138 1,510 Petition to institute a public use proceeding	
140	110	240 55 Petition to revive - unavoidable	
141	1,320	241 660 Petition to revive - unintentional	
142	1,320	242 660 Utility issue fee (or reissue)	
143	450	243 225 Design issue fee	
144	670	244 335 Plant issue fee	
122	130	122 130 Petitions to the Commissioner	
123	50	123 50 Petitions related to provisional applications	
126	240	126 240 Submission of Information Disclosure Stmt	
581	40	581 40 Recording each patent assignment per property (times number of properties)	
146	790	246 395 Filing a submission after final rejection (37 CFR 1.129(a))	
149	790	249 395 For each additional invention to be examined (37 CFR 1.129(b))	

Other fee (specify) _____

Other fee (specify) _____

* Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 0)

SUBMITTED BY

Complete (if applicable)

Typed or Printed Name	Gregory W. Steele	Reg. Number	33,796
Signature		Date	10/31/00

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: F. Haviv, *et al.*

Serial No.: (not yet assigned)
Filed: October 31, 2000

Group No.: (not yet assigned)
Examiner: (not yet assigned)

For: **N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY**

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

EXPRESS MAIL CERTIFICATE

"Express Mail" label number EL384167615US

Date of Deposit: October 31, 2000

I hereby state that the following *attached* papers or fees

Utility Patent Application Transmittal – 2 pages
Fee Transmittal, 1 pg. (in duplicate)
Application Cover Sheet – 1 pg.
Specification (61 pages); Claims (28 pages); Abstract (1 page)
Paper copy of Sequence Listing – 3 pgs.
Computer Readable Form Copy of Sequence Listing – 1 disc
Statement to Support filings and Submission in Accordance with 37 CFR 1.821 through 1.825 – 1 pg.
Two Return-Receipt Postcards

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, on the date indicated above and is addressed to the Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

Roxanne M. Swartz


Signature of person mailing paper or fee

(Express Mail Certificate)

PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: F. Haviv, et al.

Serial No.: (not yet assigned)

Filed: October 31, 2000

For: N-ALKYLATED PEPTIDES HAVING
ANTIANGIOGENIC ACTIVITY

Attorney Docket No.: 6632.US.O2

Group Art Unit: (not yet assigned)

Examiner: (not yet assigned)

Date: October 31, 2000


EXPRESS MAIL NO.: EL384167615US

Certificate of Mailing under 37 CFR §1.10:

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service as Express Mail Post Office to Addressee Service with sufficient postage in an envelope addressed to:

Box Patent Applications
Assistant Commissioner for Patents
Washington, D.C. 20231

on October 31, 2000
Name of person signing
this certificate: Roxanne M. Swartz

Signature: 

10/31/00
Jc841 U.S. PTO
09/703233

STATEMENT TO SUPPORT FILINGS AND SUBMISSIONS
IN ACCORDANCE WITH 37 C.F.R. §§1.821-1.825

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The undersigned, being the attorney of record of the above-identified patent application, submits the following statement regarding the Sequence Listing in paper and computer readable form:

I hereby state that the content of the paper and computer readable form copies of the Sequence Listing, submitted herewith, are the same.

Respectfully submitted,
F. Haviv, et al.

Abbott Laboratories
D-377/AP6D-2
100 Abbott Park Road
Abbott Park, IL 60064-6050
Telephone: (847) 937-0042
Facsimile: (847) 938-2623


Gregory W. Steele
Registration No. 33,796
Attorney for Applicants